SPStuart Phillips

Stuart Phillips

*This is an algorithmically generated author record based on publicly available information.

Stuart Phillips has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Real-World Follow-Up of People With Type 2 Diabetes Using a Mobile Diabetes App With Connected Glucose Meters Finds Improvements in Glycemia Are Durable Over 5 Years

    by Mike Grady, Stephen MacKintosh, Matthew Fryett, Stuart Phillips, Elizabeth Holt

    Objective: Evidence from long-term, real-world use of blood glucose (BG) monitoring technologies is sparse. We investigated whether using a diabetes app with connected meters could support durable diabetes management improvements in people with type 2 diabetes (T2D) over 5-years. Methods: Anonymized glucose and app analytics from 501 people with T2D were extracted from our server. The first 14 days using the app were compared with the last 14 days of each consecutive year for 5 years, using paired within-subject differences. Subjects had ≥365 BG readings per year. Results: People with T2D improved BG readings in range (RIR, 70-180 mg/dL) by +6.9 percentage points (%pts, 74.6% to 81.5%) and readings in tight range (RITR, 70-140 mg/dL) by +7.8%pts (49.2% to 57.0%) at year 1. Year 1 improvements in RIR and RITR remained evident at year 5 (+7.5%pts and +7.7%pts, respectively). Reductions in hyperglycemic readings (>180 and >250 mg/dL) explained the improvements in RIR and RITR over the 5-years. Mean BG reduced by -9.1 mg/dL at year 1 (150.2 to 141.1 mg/dL) and this was sustained at year 5 (-10.6 mg/dL, 150.2 to 139.6 mg/dL). Subjects performed BG checks at a consistent level, equivalent to 1.8 to 2.1 checks per day, over 5 years. All these glycemic changes were significant (p4 app sessions per week) effected better diabetes management. Conclusion: Real-world follow-up of people with type 2 diabetes using a diabetes app with connected meters found improvements in glycemia were durable over 5-years.


  • Clinical Accuracy of a Glucose Oxidase–Based Blood Glucose Test-Strip Across Extremes of Oxygen Partial Pressure

    by Steven Setford, Stuart Phillips, Hilary Cameron, Mike Grady

    Background: Glucose oxidase (GOx)-based blood glucose monitors (BGMs) are influenced by the partial pressure of oxygen (P o 2 ) within the applied sample. Limited in-clinic data exists regarding the quantitative effect of P o 2 in unmanipulated capillary fingertip blood samples across physiologically representative glucose and P o 2 ranges. Method: Clinical accuracy data were collected as part of a BGM manufacturer’s ongoing post-market surveillance program for a commercially available GOx-based BGM test-strip. The data set comprised 29 901 paired BGM-comparator readings and corresponding P o 2 values from 5 428 blood samples from a panel of 975 subjects. Results: A linear regression-calculated bias range of 5.22% (+0.72% [low P o 2 : 45 mm Hg] to −4.5% [high P o 2 : 105 mm Hg]); biases calculated as absolute at 2 of 75 mm Hg, a linear regression bias of +3.14% was calculated at low P o 2 , while negligible impact on bias (regression slope: +0.002%) was observed at higher than nominal levels (>75 mm Hg). When evaluating BGM performance under corner conditions of low (180 mg/dL) glucose, combined with low and high P o 2 , linear regression biases ranged from +1.52% to −5.32% within this small group of subjects and with no readings recorded at 2 . Conclusions: Data from this large-scale clinical study, performed on unmanipulated fingertip capillary bloods from a diverse diabetes population, indicate P o 2 sensitivity of the BGM to be markedly lower than published studies, which are mainly laboratory-based, requiring artificial manipulation of oxygen levels in aliquots of venous blood.


  • Distribution of Oxygen Partial Pressures in Native Capillary Fingertip Blood Samples From a Large Diabetes Patient Population

    by Steven Setford, Stuart Phillips, Hilary Cameron, Mike Grady

    A data set comprising 28 533 oxygen partial pressure (pO 2 ) values gathered from nonarterialized fingertip capillary blood samples of a large diabetes population is reported. Data were gathered routinely as part of the ongoing clinical surveillance activities of a blood glucose monitoring (BGM) system manufacturer. Overall, a mean pO 2 level of 75.3 mm Hg was recorded, with a standard deviation (SD) of 10.6 mm Hg and a range of 27.7 to 151.5 mm Hg. This data set, unique in terms of size, gathered more than 14 years at four separate clinical sites, provides a robust and comprehensive representation of an unmanipulated pO 2 fingertip capillary sample distribution, which should be of interest for physiological reasons, but also from a medical device development perspective, in which the effect of pO 2 on device performance may be an important design consideration.


  • Open Access

    Post-Market Surveillance of a Blood Glucose Test Strip Demonstrates No Evidence of Interference on Clinical Accuracy in a Large Cohort of People with Type 1 or Type 2 Diabetes

    by Stuart Phillips, Steven Setford, Mike Grady, Zuifang Liu, Hilary Cameron

    Regulations and industry guidance relating to testing for interference in blood glucose monitoring (BGM) systems continue to focus on in vitro laboratory bench tests. Post-market surveillance (PMS) in a clinical setting allows for BGM accuracy assessments to evaluate the impact of real-world exposure to polypharmacy in people with diabetes. This study evaluated the OneTouch Select Plus® BGM test-strip accuracy with respect to polypharmacy using a clinical registry dataset. Medication profiles were analysed for 1023 subjects (425 with type 1 (T1D) and 598 with type 2 diabetes (T2D)) attending 3 UK hospitals. Blood samples were analysed to determine clinical accuracy of the BGM test-strip against a laboratory comparator. 538 different medications (48 diabetes and 490 non-diabetes) were recorded across the 1023 subjects. Patients took on average 6.9 (n = 1-36) individual medications and 4.1 (n = 1-13) unique medication classes. Clinical accuracy to EN ISO 15197:2015 criteria were met irrespective of increasing average number of individual medications, categorized from 1-3, 4-6, 7-9, 10-12 and >12 taken per subject (97.7%, 97.7%, 97.8%, 97.8%, and 98.4%, respectively). Clinical accuracy criteria were met across 15 classes of medication using the combined dataset (97.9%; 29784/30433). Surveillance Error Grid (SEG) analysis showed 98.7% (29959/30368) of readings presented no clinical risk. No individual class or combination of medication classes impacted clinical accuracy of the BGM test-strip. Clinical performance for the test strip under assessment demonstrated no evidence of interference from over 500 prescription medications, with clinical accuracy maintained across a range of polypharmacy conditions in people with diabetes.


  • Open Access

    Post-Market Surveillance Assessment of the Clinical Accuracy of a Blood Glucose Monitoring System with an Improved Algorithm for Enhanced Product Performance

    by Steven Setford, Zuifang Liu, David McColl, Stuart Phillips, Hilary Cameron, Mike Grady

    Background: On-going manufacturer-led post-market surveillance (PMS), assessing the clinical accuracy of blood glucose monitoring (BGM) systems, is critical to substantiate the performance of such products for people with diabetes. Materials and Methods: Batches of Verio test-strip product were randomly and routinely selected over the period from launch of an improved-algorithm product to reporting date and sent to 3 clinic sites for clinician-led accuracy assessment. Accuracy is reported as per recently adopted FDA guidance for BGM systems, EN ISO 15197:2015 and MARD/MAD (Mean absolute relative difference/Mean absolute difference). Results: Thirty-three individual test-strip batches were evaluated corresponding to 506 unique donors. Accuracy performance - FDA: 98.9% of values within ±15% of comparator; ISO: 99.0% within ±15 mg/dL or ±15% at <100 mg/dL (<5.55 mmol/L) or ≥100 mg/dL (≥5.55 mmol/L) glucose, respectively. Overall MARD was 4.19% with a MARD range of 3.54%-5.73% across all test strip batches. Conclusions: This post-market surveillance program demonstrates the new BGM system consistently meets measures of clinical accuracy specified by regulators. This program supports a growing demand by regulators for real-world evidence demonstrating consistent in-market product efficacy as opposed to the current largely passive approach that relies on assessment of reports filed by device users.